The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
Open accessAbstract
Purpose: It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods: Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results: With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorable-intermediate, and high-risk were 7.3%, 9.2%, 38.0%, and 39.5%, respectively. In contrast, the three-tier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0%, 25.9%, and 55.2%, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95% CI, 0.61 to 0.93) were improved over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95% CI, 0.65 to 0.84), and 30% of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67% of patients would be reclassified from NCCN six-tier (very-low– to very-high–risk) by the new six-tier system. Conclusion: A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk for metastasis and can be easily incorporated into current guidelines to better risk-stratify patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607529 · Cited by 663
Self-citation
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Self-citationEsteva, A., Feng, J., van der Wal, D., Huang, S.-C., Simko, J. P., DeVries, S., Chen, E., Schaeffer, E. M., Morgan, T. M., Sun, Y., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00613-w · Cited by 217
Artificial intelligence predictive model for hormone therapy use in prostate cancer
Spratt, D. E., Tang, S., Sun, Y., Huang, H.-C., Chen, E., Mohamad, O., Armstrong, A. J., Tward, J. D., Nguyen, P. L., Lang, J. M., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300023 · Cited by 153
Spratt, D. E., Liu, V. Y. T., Michalski, J., Davicioni, E., Berlin, A., Simko, J. P., Efstathiou, J. A., Tran, P. T., Sandler, H. M., Hall, W. A., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.04.010 · Cited by 45
Self-citationGenomic classifiers and prognosis of localized prostate cancer: a systematic review
Boyer, M. J., Carpenter, D. J., Gingrich, J. R., Raman, S. R., Sirohi, D., Tabriz, A. A., Rompre-Broduer, A., Lunyera, J., Basher, F., Bitting, R. L., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00766-z · Cited by 22
Metadata
- Authors
- Spratt, D. E., Zhang, J., Santiago-Jiménez, M., Dess, R. T., Davis, J. W., Den, R. B., Dicker, A. P., Kane, C. J., Pollack, A., Stoyanova, R., Abdollah, F., Ross, A. E., Cole, A., Uchio, E., Randall, J. M., Nguyen, H., Zhao, S. G., Mehra, R., Glass, A. G., Lam, L. L. C., Chelliserry, J., du Plessis, M., Choeurng, V., Aranes, M., Kolisnik, T., Margrave, J., Alter, J., Jordan, J., Buerki, C., Yousefi, K., Haddad, Z., Davicioni, E., Trabulsi, E. J., Loeb, S., Tewari, A., Carroll, P. R., Weinmann, S., Schaeffer, E. M., Klein, E. A., Karnes, R. J., Feng, F. Y., & Nguyen, P. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-02-20
- Volume
- 36
- Issue
- 6
- Pages
- 581-590
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2769578203
- Cited by
- 211
- References
- 2
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2017.74.2940
- The paper
- Spratt, D. E., Zhang, J., Santiago-Jiménez, M., Dess, R. T., Davis, J. W., Den, R. B., Dicker, A. P., Kane, C. J., Pollack, A., Stoyanova, R., Abdollah, F., Ross, A. E., Cole, A., Uchio, E., Randall, J. M., Nguyen, H., Zhao, S. G., Mehra, R., Glass, A. G., . . . Nguyen, P. L. (2018). Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.74.2940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.